{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+B&page=20",
    "query": {
      "intervention": "Placebo Comparator B",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 2823,
    "total_pages": 283,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+B&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+B&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:28:29.163Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01474330",
      "title": "A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 33,
      "start_date": "2011-08-01",
      "completion_date": "2011-10-01",
      "has_results": false,
      "last_update_posted_date": "2019-11-12",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01474330"
    },
    {
      "nct_id": "NCT05781399",
      "title": "First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Phenylketonuria"
      ],
      "interventions": [
        {
          "name": "JNT-517 Suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo Suspension",
          "type": "DRUG"
        },
        {
          "name": "JNT-517 Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 163,
      "start_date": "2022-10-31",
      "completion_date": "2025-07-29",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 11,
      "location_summary": "Gainesville, Florida • Tampa, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05781399"
    },
    {
      "nct_id": "NCT00873912",
      "title": "A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Monovalent influenza virus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 300,
      "start_date": "2009-05",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2011-07-14",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 3,
      "location_summary": "Daytona Beach, Florida • Portland, Oregon • Austin, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00873912"
    },
    {
      "nct_id": "NCT04265534",
      "title": "KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Non-squamous Non-small-cell Lung Cancer",
        "Non-Squamous Non-Small Cell Neoplasm of Lung",
        "KEAP1 Gene Mutation",
        "NRF2 Gene Mutation",
        "NFE2L2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Telaglenastat",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Folic acid 400 -1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin B12 1000 μg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dexamethasone 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-07-24",
      "completion_date": "2022-02-09",
      "has_results": false,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04265534"
    },
    {
      "nct_id": "NCT02389998",
      "title": "Efficacy of Open Label Placebo in Children With FGIDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Functional Abdominal Pain",
        "Functional Dyspepsia",
        "Irritable Bowel Syndrome",
        "Functional Gastrointestinal Disorders"
      ],
      "interventions": [
        {
          "name": "Placebo Suspension",
          "type": "OTHER"
        },
        {
          "name": "Hyoscyamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "8 Years to 21 Years"
      },
      "enrollment_count": 31,
      "start_date": "2014-07",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2021-07-23",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02389998"
    },
    {
      "nct_id": "NCT01262365",
      "title": "Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Epratuzumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 793,
      "start_date": "2010-12",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2018-09-28",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01262365"
    },
    {
      "nct_id": "NCT00111800",
      "title": "A New Oral Treatment For Type II Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "DEN 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "DEN 7.5 mg",
          "type": "DRUG"
        },
        {
          "name": "DEN 15 mg",
          "type": "DRUG"
        },
        {
          "name": "DEN 30 mg",
          "type": "DRUG"
        },
        {
          "name": "DEN 45 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 375,
      "start_date": "2005-04-28",
      "completion_date": "2006-07-21",
      "has_results": true,
      "last_update_posted_date": "2018-03-21",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 36,
      "location_summary": "Long Beach, California • Pasadena, California • Denver, Colorado + 32 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00111800"
    },
    {
      "nct_id": "NCT00040144",
      "title": "Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "ACH126, 433",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2002-07",
      "completion_date": "2003-05",
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00040144"
    },
    {
      "nct_id": "NCT06741228",
      "title": "A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "DT120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Definium Therapeutics US, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 214,
      "start_date": "2024-12-11",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 34,
      "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06741228"
    },
    {
      "nct_id": "NCT02293148",
      "title": "Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaemia"
      ],
      "interventions": [
        {
          "name": "GSK1278863 75 mg",
          "type": "DRUG"
        },
        {
          "name": "GSK1278863 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching GSK1278863",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 61,
      "start_date": "2014-11-17",
      "completion_date": "2015-03-10",
      "has_results": false,
      "last_update_posted_date": "2018-07-24",
      "last_synced_at": "2026-11-19T06:28:29.163Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02293148"
    }
  ]
}